We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · October 22, 2020

Cabozantinib Is Safe and Effective in Advanced RCC After Progression on Prior TKI Therapy

International Journal of Urology: Official Journal of the Japanese Urological Association

 

Additional Info

International Journal of Urology: Official Journal of the Japanese Urological Association
Cabozantinib in Advanced Renal Cell Carcinoma: A Phase II, Open-Label, Single-Arm Study of Japanese Patients
Int. J. Urol. 2020 Aug 12;[EPub Ahead of Print], Y Tomita, K Tatsugami, N Nakaigawa, T Osawa, M Oya, H Kanayama, C Nakayama Kondoh, N Sassa, K Nishimura, M Nozawa, N Masumori, Y Miyoshi, S Kuroda, S Tanaka, A Kimura, S Tamada

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading